Unusual Options Activity: WFC, SNAP and Others Attract Market Bets, WFC V/OI Ratio Reaches 156.8
EST Oct 21st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57
Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Bristol-Myers Squibb Analyst Ratings
Bristol-Myers Squibb Company (BMY): A Bull Case Theory
Bristol-Myers Squibb's Quarterly Earnings Preview: What You Need to Know
Express News | Bristol-Myers Squibb Co : Bernstein Initiates Coverage With Market-Perform Rating; Target Price $56
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Bernstein begins coverage of eli lilly and co (LLY.US), gilead sciences (GILD.US), and amgen (AMGN.US), all rated as "outperforming large cap".
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Precision AQ Appoints Lance Grady as Executive Vice President, Managing Partner, Consulting Solutions
Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One'
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace
With 77% Institutional Ownership, Bristol-Myers Squibb Company (NYSE:BMY) Is a Favorite Amongst the Big Guns
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
Bristol-Myers Squibb (BMY.US) Nivolumab combined with Ipilimumab therapy approved in China
On October 14, Bristol-Myers Squibb (BMY.US) announced that its 'Dual Immune Checkpoint Therapy' application for the combination of Nivolumab and Ipilimumab has been approved by the China National Medical Products Administration (NMPA).
Express News | Bristol-Myers Squibb: Opdivo and Yervoy dual immunotherapy new indications approved in China
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know